Since 2005, Delta employees, customers and their friends and families have raised $14.8 million for BCRF. Last October alone, we raised a record-breaking $2 million for the fight.

Our campaign includes selling pink products on board and at our Delta Sky Clubs, including pink lemonade and martinis. In addition, during the month of October, Delta will donate 10% of all on-board sales and 100% of all on-board sales on Mother’s Day to BCRF.

That’s why at Delta we dedicate one percent of our profits to supporting communities worldwide where we live, work and serve.

    •  
    • Designer Zac Posen has gotten in on the effort, joining forces with Delta to design a new pink dress, along with five other pink uniform pieces, as part of our new uniform collection that debuted earlier this year.
    •  
    • This month, Delta is celebrating its 14th anniversary of the Breast Cancer One employee survivor flight. This kids off the airline’s Breast Cancer Awareness Month campaign throughout October and continues the tradition of building awareness and raising funds for the Breast Cancer Research Foundation.

  • BCRF and Delta

    Delta’s pride in contributing to life-saving breast cancer research is visible to all our customers in our 2018 onboard video shown through the month of October.


  • BCRF’s Immunotherapy Initiative

    Immunotherapy is one of the most exciting areas in breast cancer research. We're highlighting how BCRF-supported researchers are moving this field forward with innovative approaches such as cryoablation.


  • About BCRF PSA

    This year, BCRF is investing $63 million to support the work of nearly 300 scientists at leading medical and academic institutions across 14 countries, making BCRF the largest private funder of breast cancer research worldwide.


  • A Mom on a Mission to Change her Family’s Future

    Pheodora Shin, a physician diagnosed at age 45, supports research so her daughter won’t follow in her footsteps.


  • A Tragic Loss. A Daughter’s Commitment to Changing the Story

    After losing her mother to metastatic breast cancer, BCRF Staff Member Margaret Flowers rerouted her career path from chef to scientist.


  • If Not For BCRF

    BCRF-funded investigators have been deeply involved in every major breakthrough in breast cancer prevention, diagnosis, treatment and survivorship since its founding nearly 25 years ago.


  • Why Research

    Why does BCRF focus on research? Because investing in research produces real results. Hear from BCRF’s world-recognized scientists about how research is improving care, producing better outcomes and transforming lives—every day.

  •  
     
  • Dr. Jack Cuzick, Queen Mary, University of London, United Kingdom &
    Dr. Prudence Francis, University of Melbourne, Australia

    Improving risk assessment in high-risk women. The goal of the BCRF research led by Drs. Cuzick and Francis is to more precisely identify risks for individual women based on protein and gene biomarkers that can predict outcomes for the prevention and treatment of breast cancer. To do this, they created a High Risk Breast Bio-Bank (HRBB) that includes blood, tumor tissue, and mammograms with clinical outcome data and long-term follow-up of individual women in prevention and treatment trials. In the coming year, they will continue tissue collection for the HRBB, adding samples from three new trials, expanding this excellent resource for future translational research.

    Bio: Dr. Francis: Associate Professor Prue Francis is Head of Medical Oncology in the Breast Service at the Peter MacCallum Cancer Centre and also a consultant Medical Oncologist at St Vincent’s Hospital Melbourne. She holds an academic appointment as an Associate Professor at The University of Melbourne. Associate Professor Francis graduated from The University of Melbourne and completed her internal medicine and medical oncology training in Melbourne and in New York at the Memorial Sloan Kettering Cancer Centre. She is Vice Chair of the Scientific Advisory Committee of the ANZBCTG, holds an appointment as Conjoint Associate Professor at The University of Newcastle in the School of Medicine and Public Health and is a member of the Scientific Committee of the International Breast Cancer Study Group (IBCSG).
  •  
  • Dr. Rosette Lidereau, Institut Curie, France
    Identifying new therapeutic targets in metastatic breast cancer. Dr. Lidereau's BCRF project focuses on understanding the processes involved in metastasis, particularly how tumor cells can migrate, or move from one place to another, a characteristic that normal breast cells do not have. Her lab identified an essential protein called Kindlin-1 that is over-expressed in cancer cells. Kindlin-1 causes tumor cells to become mobile and increases their ability to invade (break through) neighboring tissue. In the coming year, Dr. Lidereau will continue her efforts to block kindlin-1 to prevent tumor progression. These studies may lead to new therapeutic strategies for aggressive breast cancers.
  •  
  • Dr. Anne McTiernan, Fred Hutchinson Cancer Research Center, University of Washington
    Uncovering the link between obesity and breast cancer to reduce breast cancer cases and improve outcomes.

    Being overweight or obese increases the risk of breast cancer after menopause and adversely affects survival after a breast cancer diagnosis at any age. Therefore, uncovering the links among obesity, physical activity, and cancer-related biomarkers has high potential for reducing breast cancer risk and improving survival. Dr. McTiernan’s team is studying the immediate effects of exercise on molecular markers of breast cancer risk. Women will be randomized to either: 1) a 45-minute exercise bout; or 2) a 45-minute resting control group. Before and after the exercise (or rest), and after an additional hour, Dr. McTiernan’s team will collect blood to measure breast cancer biomarkers, including insulin, glucose, and insulin resistance. This study is unique in focusing on the acute effects of exercise on biomarkers of breast cancer risk and could help support guidelines for daily exercise for breast cancer prevention and provide evidence that exercise even without weight loss is beneficial.
  •  
  • Dr. Hedvig Hricak, Memorial Sloan Kettering Cancer Center
    Improving quality of breast cancer screening and diagnosis in low-resource settings. With BCRF support since 2004, Dr. Hricak and colleagues at Memorial Sloan Kettering Cancer Center have established and maintained a global, world-class clinical research training program in breast imaging. This program provides selected radiologists from around the world with intensive, individualized instruction in breast imaging interpretation and clinical research methodology with the goal of standardizing best practices and fostering international collaborations to improve patient care and outcomes. Dr. Hricak has established important connections in 14 countries and regions to provide the most promising candidates for training. In the upcoming year, Dr. Hricak and team will train a BCRF Fellow who will participate in cutting-edge research combining imaging and genomics studies to improve the accuracy of breast cancer diagnoses. Dr. Hricak was selected by the BCRF Scientific Advisory Board to receive the 2018 Jill Rose Award for seminal contributions in merging imaging technology with the molecular medicine revolution.
  •  
  • Dr. Arti Hurria, City of Hope Comprehensive Cancer Center
    Focusing on older breast cancer patients to improve quality of life and breast cancer outcomes. There is limited data to guide physicians on treatment recommendations for older women with breast cancer, despite this population comprising almost half of the projected breast cancer diagnoses in 2017. Studies show that this population is at increased risk for chemotherapy-related side effects, yet no standard method exists to identify vulnerable individuals. To address this issue, Dr. Hurria's team is conducting a study to understand how chemotherapy impacts the health and functioning of older adults with breast cancer. They have completed enrollment to a multi-center study of 500 adults age 65 and older with stage I-III breast cancer who will receive chemotherapy. They are following these patients from pre-chemotherapy to the end of treatment in order to examine the association between chemotherapy and changes in the patients’ ability to complete daily activities.
  •  
  • Dr. Sofia Merajver, University of Michigan
    Pursuing novel approaches to understanding metastasis and developing new treatment strategies. Very aggressive breast cancers such as inflammatory breast cancer, triple negative breast cancer, and other rapidly progressive breast cancers have acquired the ability to promote cancer cell motility and the cancer's ability to survive in diverse organ locations. Dr. Merajver's team has devised new avenues to attack aggressive cancer cells when they are moving. They designed and are testing simple synthetic devices to identify which specific cells are already capable of metastasizing (spread to other organs) early in aggressive breast cancers. These studies may guide therapies that prevent metastases in women diagnosed with aggressive breast cancer.
  •  
  • Stanislav Emelianov, PhD, Georgia Institute of Technology and Emory School of MedicineAtlanta, Georgia
    Advancing technologies to improve screening, diagnosis and monitoring of breast cancer The overall goal of Dr. Emelianov’s research is to develop and translate emerging ultrasound imaging technologies, augmented with molecularly targeted theranostic agents. This will result in an imaging platform capable of non-invasive, diagnostic imaging and image-guided therapy of breast cancer. Today, mammography – an X-ray of the breast – is the leading and recommended modality to screen for breast cancers. Dr. Emelianov’s research is focused on design and development of a new clinical breast cancer imaging system based in ultrasound technology, and synthesis and characterization of clinically relevant smart theranostic agents. The goal is more precise screening and surveillance, and targeted delivery of tumor killing drugs.

    Bio: Dr. Emelianov is a Joseph M. Pettit Endowed Chair, Georgia Research Alliance Eminent Scholar, and Professor of Biomedical Engineering and Electrical & Computer Engineering at the Georgia Institute of Technology and Director of the Ultrasound Imaging and Therapeutics Research Laboratory at the Georgia Institute of Technology. Dr. Emelianov’s career has been devoted to the development of advanced imaging methods, assisting treatment planning, and enhancing image-guided therapy and monitoring of the treatment outcome.
 

Thank you for visiting the DeltaShop Store.

If you have items in your cart they will not transfer over to the InvoiceWorks site. If you wish to purchase via credit card, please click CANCEL and complete the order within Delta Shop. Otherwise, click PROCEED to continue to InvoiceWorks.

Thank you for visiting DeltaShop.

You are about enter the Delta Galleria which features expanded options of custom Delta-branded merchandise.

If you have items in your cart they will not transfer over to the Delta Galleria site. If you wish to purchase via credit card, please click CANCEL and complete the order within DeltaShop. Otherwise, click PROCEED to continue to the Delta Galleria.

powered by Essent® • SiteBuilder Pro